Lyfgenia (lovotibeglogene autotemcel) — Coverage Criteria
Customize your policy alerts
Sign up for univerahealthcare Policy PHARMACY-119 alerts
Get alerted when Policy PHARMACY-119 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for Lyfgenia (lovotibeglogene autotemcel) for members across applicable lines of business, including clinical eligibility, exclusions, and utilization rules for one-time gene therapy administration.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lyfgenia
Initial therapy
Covered when ALL of the following are met:
Authorization issued for up to 6 months to allow time for administration; single‑administration only; minimum recommended cell dose required.
Retreatment / prior gene therapy
Not eligible / investigational conditions:
Includes prior autologous cellular therapies and prior gene therapy/editing products.
Coverage stance on administration and retreatment — single administration emphasized
Covered when ALL of the following are met (policy emphasizes single administration):
Policy states most gene and cellular therapies are designed and studied as single‑administration interventions.
Retreatment is not authorized.
Includes switching between autologous/allogeneic products, sequential CAR‑T/TCR‑T/NK‑cell therapies, or in‑vivo gene therapy following prior vector‑based therapy.
Requests for Lyfgenia will be denied for individuals who meet any of the explicit exclusion criteria. Exclusions include: an accessible and willing 10/10 HLA‑matched related donor; prior treatment with an allogeneic stem cell transplant; prior treatment with a gene therapy or gene‑editing product; clinically significant active bacterial, viral, fungal, or parasitic infection; history of severe cerebral vasculopathy (including overt or hemorrhagic stroke, abnormal transcranial Doppler ≥200 cm/sec requiring chronic transfusion, occlusion/stenosis in the polygon of Willis, or Moyamoya disease); advanced liver disease (persistent AST, ALT, or direct bilirubin >3× ULN; baseline PT/PTT >1.5× ULN; history of cirrhosis or bridging fibrosis; or active hepatitis); baseline creatinine clearance ≤ 70 mL/min/1.73 m2 (documentation required); contraindications to plerixafor, busulfan, or conditioning agents (including hypersensitivity to active substances/excipients); prior or current malignancy or immunodeficiency (with limited exceptions for previously treated, non–life‑threatening cured tumors); an immediate family member with a known or suspected familial cancer syndrome; or two or more α‑globin gene deletions (documentation required).
Individuals who have previously received gene or cellular therapies are generally not eligible for additional gene or cellular therapy including Lyfgenia. Examples include prior receipt of any autologous cellular therapy (e.g., CAR‑T, TCR‑T), any allogeneic genetically modified cellular therapy, any in vivo gene therapy (such as AAV or lentiviral vector), or any ex vivo gene‑modified cell product. Requests for additional or sequential gene/cellular therapies after prior exposure may be denied unless there is documented evidence supporting safety and anticipated clinical benefit.
Lyfgenia is considered investigational when the policy’s coverage criteria are not met. Lyfgenia is also considered investigational for all other unapproved indications and will not be authorized for retreatment; the product is indicated for one‑time single‑dose intravenous use only and retreatment after prior administration is considered experimental/investigational.
Retreatment with the same product or sequential administration of additional or different gene/cellular therapies is considered experimental and investigational. The policy emphasizes that gene and cellular therapies are evaluated as one‑time administrations, and repeat dosing has not been established as safe or effective; therefore retreatment or sequential therapy is not supported and may be denied.
Coding and Laboratory Thresholds
| J3394 | HCPCS code listed for Lyfgenia |
Provider Actions, Authorization, and Documentation
Prior authorization required; 6-month authorization for single-dose administration
Prior authorization is required for Lyfgenia; approvals are issued for a 6-month period to allow time for cell collection, manufacturing, and single-dose administration. Authorization applies to a one-time single-dose (single-administration) infusion only; retreatment is considered investigational and will not be authorized under this approval.
- Approval period: 6 months to allow sufficient time for administration
- Authorization applies to a single-dose, one-time administration
Use HCPCS J3394 for prior authorization/reimbursement
Prior authorization and reimbursement decisions reference HCPCS code J3394 for Lyfgenia. Coverage and payment remain subject to the member’s subscriber contract and applicable benefit rules.
- HCPCS code: J3394
- Eligibility for reimbursement depends on member benefits and plan documents
Hydroxyurea trial ≥6 months at max tolerated dosing required (unless contraindicated)
The patient must have completed a trial of hydroxyurea for at least 6 consecutive months at maximum tolerated dosing and experienced therapeutic failure, intolerance, or have a contraindication; two hematologic toxicities leading to discontinuation also satisfy the requirement.
- Therapeutic failure example: continued frequent/severe VOCs or ongoing frequent transfusion requirements despite adherence
- Adherence may be verified via pharmacy refill history, pharmacy profile, or progress notes
No step-therapy pathways for sequential gene/cellular therapies; sequential use considered investigational
There is no supported step-therapy pathway beyond the hydroxyurea requirement; sequential use of additional or different gene or cellular therapies after prior exposure is considered experimental/investigational and is not supported.
- Sequential administration (e.g., switching between CAR-T products, autologous→allogeneic switches, CAR-T/TCR-T/NK sequential use) is considered experimental/investigational
- Receiving another gene therapy after prior vector-based therapy is not supported
Submit complete clinical documentation with each request
Clinical documentation must be submitted with each prior authorization request and should include progress notes, prior treatment history (including hydroxyurea use and adherence), dosing and administration plans, and any prior cellular or gene therapy history.
- Progress notes documenting disease course and prior therapies
- Treatment history including hydroxyurea trial details and adherence evidence
- Documentation of any prior cellular or gene therapy exposure
Provide negative HBV/HCV/HIV tests (within 3 months) and genotype/lab documentation
Laboratory documentation required includes negative screening results for HBV, HCV, and HIV‑1/2 obtained within the prior 3 months, and laboratory evidence supporting eligibility (e.g., baseline creatinine clearance), plus genotype documentation as specified in the clinical criteria.
- Negative HBV, HCV, and HIV‑1/2 test results within 3 months prior to cell collection
- Documentation of sickle cell genotype (βS/βS, βS/β0, or βS/β+)
- Baseline creatinine clearance documentation (see exclusion thresholds)
Reimbursement depends on member contract; codes may not be covered in all circumstances
Reimbursement is contingent on the member’s subscriber contract and applicable benefit rules; codes may not be covered in all circumstances and inclusion in this policy does not guarantee payment.
- Verify coverage under the member’s contract before assuming reimbursement
- Policy and coding statements should be read carefully for plan-specific exclusions
Explicit exclusion conditions that will lead to denial
Requests will be denied if the patient meets any explicit exclusion: has an accessible and willing 10/10 HLA‑matched related donor, prior allogeneic transplant, prior gene therapy/editing product, active clinically significant infection, severe cerebral vasculopathy, advanced liver disease, baseline creatinine clearance ≤70 mL/min/1.73 m2, contraindication to mobilization or conditioning agents, prior/current malignancy or immunodeficiency (with limited exceptions), immediate family familial cancer syndrome, or two or more α‑globin gene deletions.
- Accessible willing 10/10 HLA‑matched related donor → not eligible
- Prior allogeneic transplant or prior gene therapy/editing product → not eligible
- Baseline creatinine clearance ≤70 mL/min/1.73 m2 → not eligible (document within 3 months)
Retreatment or sequential gene/cellular therapy requests considered investigational — denial risk
Requests for retreatment (repeat administration) or for sequential administration of an additional or different gene/cellular therapy after prior exposure are considered experimental and investigational and may be denied.
- Retreatment with the same product is considered investigational due to lack of established safety, efficacy, and durability
- Any additional or sequential gene/cellular therapy after prior exposure is considered experimental/investigational
Initial Therapy Authorization Criteria
Initial therapy — Initial authorization criteria and dosing
Initial authorization criteria and dosing:
Refer to FDA‑approved prescribing information for complete dosing and administration instructions. Authorization is for a single administration; approvals issued for 6 months to allow time for scheduling/administration.
Initial Therapy — Initial administration guidance
Initial administration guidance:
Policy emphasizes one‑time administration; retreatment is considered experimental/investigational.
Continuation and Post-Treatment Rules
Continuation therapy rules — Post‑treatment continuation
Post‑treatment continuation rules:
Continuation beyond single administration is not supported.
Continuation Therapy — Continuation or retreatment rules
Continuation or retreatment rules:
Individuals previously receiving any autologous cellular therapy, any allogeneic genetically modified cellular therapy, any in vivo gene therapy, or any ex vivo gene‑modified cell product are generally not eligible for additional gene or cellular therapy.
Step Therapy Requirements
| Requirement | Details |
|---|---|
| Hydroxyurea trial duration | |
| Patients must have undergone a trial of hydroxyurea for ≥ 6 consecutive months at maximum tolerated dosing unless there is a contraindication or therapy was discontinued for hematologic toxicity after two events. | |
| Therapeutic failure definition | |
| Therapeutic failure includes continued frequent and/or severe vaso-occlusive events (VOCs/VOEs) or ongoing frequent transfusion requirements despite adherence to hydroxyurea for the ≥ 6-month trial. Adherence may be assessed by pharmacy refill history, pharmacy profile, or progress notes documenting use of samples. | |
| Contraindication to hydroxyurea | |
| Contraindication defined as hypersensitivity to hydroxyurea or any component of the formulation; documented contraindication satisfies the requirement in lieu of a trial. | |
| Hematologic toxicity criteria | |
| Hematologic toxicity is defined by neutrophil, platelet, hemoglobin, and/or reticulocyte count abnormalities concurrent with hydroxyurea use; after the first event therapy can be stopped and restarted with dose reduction upon recovery; two hematologic toxicities leading to discontinuation meet the requirement. |
| Coverage stance | Policy statement |
|---|---|
| Sequential or additional gene/cellular therapies | |
| Sequential administration of an additional or different gene or cellular therapy after prior exposure is considered experimental and investigational; safety, efficacy, and clinical benefit of sequential use have not been established. | |
| Retreatment with same product | |
| Repeat dosing, reinfusion, or retreatment with the same gene or cellular therapy product is considered experimental and investigational because trials evaluated these as single-administration interventions and safety, efficacy, and durability of a second administration are not established. | |
| Prior gene/cellular therapy exposure | |
| Individuals who previously received any autologous cellular therapy, any allogeneic genetically modified cellular therapy, any in vivo gene therapy (e.g., AAV, lentiviral vector), or any ex vivo gene-modified cell product are generally not eligible for additional gene or cellular therapy. |
Quantity Limits and Dosing
Site of Care and Administration
Site-of-care may affect approval timeframe — administered in center-based infusion setting
Site of care may affect the approval timeframe; Lyfgenia is administered by a healthcare professional and is typically provided in a center-based infusion setting.
- The requested site of care is subject to review and may influence authorization timing.
Site-of-care details not specified in policy
No additional site-of-care specifics are provided in this policy section beyond noting that administration is healthcare professional–administered and site review may affect timing.
Background on Disease and Therapy
Sickle cell disease (SCD) is an inherited group of hemoglobin disorders caused by polymerization of hemoglobin S (HbS) leading to red blood cell sickling, chronic hemolysis, and vaso‑occlusion. This pathophysiology produces acute complications such as vaso‑occlusive events (painful crises), acute chest syndrome, and stroke, and results in progressive multi‑organ morbidity. Disease‑modifying therapies (for example, hydroxyurea) and hematopoietic stem cell transplantation can reduce disease burden or provide cure in select patients, but limitations include treatment failure, toxicity, donor availability, and transplant‑related risks; gene and cellular therapies have been developed to address these gaps by modifying autologous cells to reduce HbS polymerization and sickling.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.